Palvella Therapeutics, Inc. (PVLA) Earnings
Palvella Therapeutics, Inc. is expected to report next earnings on August 13, 2026 (in NaN days), with a consensus EPS estimate of $-1.16. PVLA has beaten EPS estimates in 5 of its last 10 reported quarters (average surprise -20.8% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-0.90 | $-1.20 | -33.3% | — | — |
| Mar 31, 2026 | $-0.91 | $-1.08 | -18.5% | — | — |
| Nov 11, 2025 | $-0.85 | $-1.03 | -21.2% | — | — |
| Aug 14, 2025 | $-0.78 | $-0.86 | -10.3% | — | — |
| May 15, 2025 | $-3.40 | $-0.74 | +78.2% | — | — |
| Mar 31, 2025 | $-0.39 | $4.00 | +1125.6% | — | — |
| Aug 14, 2024 | $-2.40 | $-2.76 | -15.0% | — | — |
| May 15, 2024 | $-4.80 | $-2.00 | +58.3% | — | — |
| Nov 14, 2023 | $-8.80 | $-8.70 | +1.1% | $20M | +152.1% |
| Aug 10, 2023 | $-12.54 | $3.62 | +128.9% | $20M | +399.0% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 7, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Highlights include progress toward NDA submission for microcystic lymphatic malformations, clinical program progress in various rare disease indications, addition of commercial and medical leadership, and successful $230 million financing in Q1
Guidance
Guidance includes NDA submission expected in second half of 2026, phase 3 study initiation for cutaneous venous malformations in second half of 2026, phase 2 results expected for angiokeratomas in second half of 2027, and plans for commercial launch preparation
Segment performance
Not explicitly detailed in terms of absolute financial figures and revenue contribution percentages for product segments, but focuses on clinical program progress and pipeline for rare skin diseases and vascular malformations
Risks & headwinds
Not extensively discussed in terms of specific risks and operational failures in the provided transcript
Analyst Q&A
Q: How do you think about which programs or indications will require a placebo arm versus which may be single arm for pivotal trials?
A: That's disease-specific. For microcystic lymphatic malformations, which have no spontaneous regression, single-arm study can be reliable. It's very disease specific as some diseases have spontaneous improvement requiring placebo-controlled trials...
Q: Following the European patent on Keturian rapamycin, how are you thinking about that approach for ex-US market to expand Keturian rapamycin?
A: See significant market opportunities outside US. Post phase three data, received inbound interest from licensing partners. Prefer maintain focus on US market initially, then intensify partnering discussions post-FDA approval